Fluorodopa F 18

(Fluorodopa F 18®)

Fluorodopa F 18

Drug updated on 11/14/2023

Dosage FormInjection (intravenous: 15.5 MBq/mL to 308.2 MBq/mL (0.42 mCi/mL to 8.33 mCi/mL))
Drug ClassRadioactive diagnostic agents
Ongoing and
Completed Studies


  • Indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). Fluorodopa F 18 PET is an adjunct to other diagnostic evaluations.

Product Monograph / Prescribing Information

Document TitleYearSource
Fluorodopa F 18 Prescribing Information.2019The Feinstein Institutes for Medical Research, Manhasset, NY

Systematic Reviews / Meta-Analyses